NCT07115654View on ClinicalTrials.gov

BCMA/CD3 BsAb Therapy for POEMS Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
POEMS Syndrome
Interventions
DRUG

CM336 (BCMA/CD3 bispecific antibody)

CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.

Trial Locations (1)

300020

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER